The addition of PDL-1 inhibitors to traditional chemotherapy regimens in several trials has been associated with a higher rate of pathological complete response (pCR) as PD-L1 tumor expression increases (PD-L1 >50%, odds ratio of pCR = 44.7, 95% CI 28.6–61.7 vs. PD-L1 < 1% = 16.7, 95% CI = 9.2–26.8) [67]. This evidence concerns the gene CD274 and neoplasm.